McKesson Specialty Health and US Oncology Network expanded their agreement with the National Comprehensive Cancer Network, adding five disease states to NCCN Value Pathways.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
